Brain-derived neurotrophic factor (BDNF) supports hippocampal, cortical and basal forebrain cholinergic neurons, which lose function in Alzheimer's disease. In Alzheimer's tissues such as hippocampus and parietal cortex, brainderived neurotrophic factor mRNA is decreased three-to fourfold compared with controls. However, the molecular mechanism of the down-regulation of BDNF in Alzheimer's disease is unknown. The human brain-derived neurotrophic factor gene has multiple promoters governing six non-coding upstream exons that are spliced to one downstream coding exon, leading to six different transcripts. Here we report an alternate human splice variant within exon 4I for a total of seven transcripts. Previous brain-derived neurotrophic factor mRNA measurements in Alzheimer's disease tissue were done using the downstream coding exon present in all transcripts. Using RT-PCR primers specific for each upstream exon, we observe a significant decrease in three human brainderived neurotrophic factor mRNA transcripts in Alzheimer's disease samples compared with controls. Transcripts 1 and 3 each exhibit a two-fold decrease, and transcript 2 shows a five-fold decrease. There are no significant differences between control and Alzheimer's disease samples for the other transcripts, including the new splice variant. In rat, both transcripts 1 and 3 are regulated through the transcription factor cAMP response element binding protein, whose phosphorylation is decreased in the Alzheimer's disease brain. This could lead to specific down-regulation of the brainderived neurotrophic factor transcripts shown here.
Brain-derived neurotrophic factor (BDNF) is highly expressed and is distributed widely throughout the CNS, specifically in the hippocampal formation, cerebral cortex, and amygdaloid complex Hofer et al. 1990; Phillips et al. 1990; Wetmore et al. 1990) . BDNF promotes the survival and function of hippocampal and cortical neurons (Ghosh et al. 1994; Lindholm et al. 1996; Lowenstein and Arsenault 1996) , cholinergic neurons (Alderson et al. 1990; Knusel et al. 1991) and nigral dopaminergic neurons (Hyman et al. 1991; Knusel et al. 1991) . BDNF is also important for synaptic transmission and the excitatory properties of these neurons (Patterson et al. 1992; Castren et al. 1993; Dragunow et al. 1993; Kang and Schuman 1995; Scharfman 1997; Osehobo et al. 1999; McLean et al. 2000) .
Basal forebrain cholinergic, cortical, and hippocampal neurons lose function and synaptic connectivity in Alzheimer's disease (AD) (Coyle et al. 1983; Whitehouse et al. 1982; Cuello and Sofroniew 1984; Etienne et al. 1986; Hefti and Weiner 1986; Mann 1991) . This may occur because of a deficit in BDNF in the AD brain. A 3-4-fold reduction in BDNF mRNA has been amply documented in the hippocampus and parietal cortex (Phillips et al. 1991; Holsinger et al. 2000) . Protein levels of BDNF have been shown to decrease in Alzheimer's disease entorhinal cortex, hippocampus and temporal, frontal and parietal cortex (NarisawaSaito et al. 1996; Connor et al. 1997; Ferrer et al. 1999; Hock et al. 2000) . However, the transcriptional regulation of the human BDNF gene has not been studied, and so the mechanism of the decrease in BDNF levels in the AD brain is not well understood.
In the rat, the BDNF gene has been shown to have four 5¢ exons and one 3¢ exon . The four 5¢ exons each have upstream promoters and each is individually spliced to the 3¢ exon (encoding the mature protein) to give four different transcripts. Downstream of the 3¢ exon there are two polyadenylation sites, which give two different length transcripts for each upstream exon, totaling eight splice variants . The presence of multiple promoters in the BDNF gene allow for differential mechanisms of activation and tissue-specific expression in the CNS (Falkenberg et al. 1992; Metsis et al. 1993; Kokaia et al. 1994; Timmusk et al. 1995) .
The human BDNF gene is structurally similar to the rat gene (Maisonpierre et al. 1991) . The human BDNF gene contains two additional non-coding exons compared with rat (4I and 5U), but only one polyadenylation site is present downstream from the 3¢ coding exon (Aoyama et al. 2001) . The six upstream exons in the human BDNF gene give rise to six transcripts, although the additional exons produce transcripts by differential splicing, not additional promoters (Aoyama et al. 2001) . Previous measurements documenting decreased BDNF mRNA in the AD brain targeted the coding exon (exon5) present in all transcripts and therefore examined total BDNF mRNA levels. In this study, we used RT-PCR with upstream primers specific for each exon to determine which of the transcripts is responsible for the reduced BDNF mRNA in AD brain.
Materials and methods
Human post-mortem brain tissue Parietal cortex tissue samples from normal, neurologically unimpaired subjects (n ¼ 12; six females, six males) and from subjects with AD (n ¼ 12; six females and six males) were provided by the Institute for Brain Aging and Dementia Tissue Repository at the University of California, Irvine. A diagnosis of AD was confirmed by pathological and clinical criteria (McKhann et al. 1984; Khatchaturian 1985) . Control and AD samples were matched for age and gender. Tissue was frozen at autopsy and stored at )80°C until use.
RNA isolation
Total cellular RNA was purified from parietal cortex samples using TRIzol TM Reagent (Gibco BRL, Burlington, Ontario, Canada) following the manufacturer's protocol. Samples exhibiting an absorbance ratio (260/280) greater than or equal to 1.7 and exhibiting strong 28S and 18S ribosomal RNA bands on 0.01-g/mL agarose gels were used for further analysis.
Primers for BDNF transcripts and b-actin Human BDNF primer sequences were kindly provided by Dr Mineyoshi Aoyama, Department of Bioregulation Research, Nagoya City University Medical School, Mizuho-ku, Nagoya, Japan. b-Actin primer sequences were previously described (St Amand et al. 1996) . Primers were synthesized at the Central Facility of the Institute for Molecular Biology and Biotechnology (MOBIX) at McMaster University.
RT-PCR
For determination of transcripts 2 and 5U, RNA samples were treated with DNaseI (1.0 lL/10 lg total RNA; Ambion, Austin, TX, USA) at 37°C for 30 min, followed by 2 lL of DNase Inactivation reagent. For all other transcripts, RNA samples did not undergo DNase treatment. Ten micrograms total RNA from human parietal cortex was reverse transcribed into cDNA using the GeneAmpÒ RNA PCR kit (Perkin Elmer, Norwalk, CT, USA). PCR was performed in the GeneAmp PCR system 2400 using 5 lL aliquots of the reverse transcriptase reaction mixture with 0.35 lM each of the 3¢ and 5¢ primers, 16.8 lCi of 33 P-dCTP, and 2.5 U AmpliTaq Gold (Perkin Elmer). Optimization was performed for all primer sets to determine an optimal cycle number within the logarithmic phase of amplification. Cycle optimization for transcripts are as follows, transcript 1, 35 cycles, transcript 2, 34 cycles, transcript 3, 35 cycles, transcript 4, 32 cycles, transcript 4I, 38 cycles, transcript 5U, 35 cycles, and b-actin, 22 cycles. The amplification profile included an initial activation of the Taq polymerase for 12 min at 95°C, denaturation for 30 s at 94°C followed by annealing at 58°C for 30 s, extension at 72°C for 45 s, and a final extension at 72°C for 7 min. For b-actin, annealing was at 64°C for 30 s and extension at 72°C for 1 min. Four to five independent RT-PCRs were performed for each primer pair.
Isolation and sequencing of RT-PCR products
Amplified RT-PCR product from transcript 4I gave two bands upon electrophoresis in a 0.018-g/mL agarose gel in the presence of ethidium bromide. Single bands were cut from the gel, and DNA was isolated using QIAquick TM Gel Extraction Kit (Qiagen, Mississauga, ON, Canada). The isolated bands were sequenced in both directions, using transcript 4I PCR primers, by the Central Facility of the Institute for Molecular Biology and Biotechnology (MOBIX) at McMaster University.
Quantitative and statistical analysis Ten microliters of each RT-PCR reaction mixture was subjected to electrophoresis in a 0.018-g/mL agarose gel and analyzed by phosphorimagery using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). Quantitation was accomplished by placing rectangular cursors of fixed dimensions over each band and measuring pixel density for each sample, with local background subtraction. Four to five separate RT-PCR experiments were performed for each primer pair on each subject; the mean value of these experiments was used in the statistical analysis (Table 1) . For transcripts with extremely low expression levels as indicated by pixel values, specifically transcripts 2, 4I, and 5U, only two RT-PCR experiments were averaged for each subject. For statistical analysis of group differences in transcript expression, a two-way ANOVA was used [group (control versus AD subjects) · transcripts (1, 2, 3, 4, 4I, 4Ia, and 5U)], followed by two-tailed t-tests to determine significance between groups for each transcript. Box plot analysis identified extreme outliers in transcripts 2, 3 and 5U (Table 1) . These outliers were eliminated from the two-way ANOVA, post-hoc Values listed are pixel density values ± SEM. Numbers 1 through 24 in the vertical column identify the samples used with BDNF transcripts and standard error of the mean listed in the top horizontal row. The pixel values that are underlined are extreme outliers.
t-tests and Fig. 3 . Comparisons of the effects of age and postmortem interval on yield of total RNA were done by regression analysis and two-samples paired t-tests. All statistics were calculated and results graphed using Microsoft Excel (Microsoft, WA, USA) and SPSS 10.1 software (SPSS Inc., Chicago, IL, USA).
Results

Samples
The samples consisted of 12 control and 12 AD post-mortem parietal cortex samples. The average age of the subjects in the control group was 77.58 ± 2.63 years and that of the AD group was 78 ± 2.49 years ( p ¼ 0.9). The average postmortem delay was 6.23 ± 0.039 h for the control group but only 3.05 ± 0.028 hours for the AD subjects ( p < 0.001). However, no significant differences were observed in the yield of total RNA extracted from both groups (485. We have previously demonstrated no significant correlation between BDNF mRNA content and age or post-mortem delay in both control and AD parietal cortex samples (Holsinger et al. 2000) .
New alternative splice site in transcript 4I
The reported size of transcript 4I is 414 bp (Aoyama et al. 2001) . Upon PCR amplification, the 414 bp band was faintly present but was secondary in intensity to a 313-bp band (Fig. 1) . Purification and sequence analysis of the 313-bp band revealed a new splice variant of exon 4I with splicing occurring 151 bp from the start of the 5¢ primer and splicing out a 101-bp sequence (Fig. 2) .
b-Actin control
To control for variation between samples we used the constitutively expressed cytoskeletal protein, b-actin. Previous studies from ours and other laboratories have shown no significant difference in b-actin levels between normal and AD subjects (Takeda et al. 1991; Takeda et al. 1992; Holsinger et al. 2000) . Our results support these previous findings; statistical comparisons between control and AD samples yielded no significant difference in b-actin mRNA levels (Fig. 3 , p > 0.05).
Transcripts 1, 2 and 3 are decreased in AD parietal cortex The two-way ANOVA revealed that overall expression of transcripts was significantly lower in AD patients compared Brain-derived neurotrophic factor transcripts 1061 with controls [for group, F 6,162 ¼ 4.998, p < 0.001)]. This is consistent with our previous results using the coding exon of BDNF as the RT-PCR target (Holsinger et al. 2000) . Tests of between-subjects effects revealed a significant difference in individual transcripts. (Fig. 3) .
Discussion
Using RT-PCR on 24 age-and gender-matched control and AD samples from the parietal cortex, we report a significant decrease in three human BDNF mRNA transcripts in the parietal cortex of AD samples compared with controls. A two-way ANOVA showed a significant effect for group and group · transcript. Post-hoc t-tests revealed a significant difference between control and AD samples for transcript 1, transcript 2 and transcript 3. None of the other transcripts (4, 4I, 4Ia or 5U) demonstrated any significant differences. We have previously shown that BDNF mRNA levels are decreased in the AD parietal cortex compared with controls (Holsinger et al. 2000) . The decreased expression we demonstrate here in transcripts 1, 2 and 3 in AD could account for the decreased BDNF expression seen in previous studies examining the coding exon. Six non-coding exons and their resulting transcripts have been reported for the human BDNF gene (exons 1, 2, 3, 4, 4I and 5U) (Aoyama et al. 2001) . Within transcript 4I, we noted a new splice variant that was more highly expressed in parietal cortex tissue than the original 414 bp transcript 4I reported by Aoyama et al. (2001) . Sequence analysis revealed a different splice variant of the 4I transcript (4Ia) containing a 101-bp deletion.
Although the regulatory elements and factors governing human BDNF expression are not known, we can draw parallels with the control of BDNF expression in the rat. In the rat, promoters I and III are both regulated by calcium (Tao et al. 1998; Tabuchi et al. 2000) . Calcium influx leads to cAMP response element binding protein (CREB) phosphorylation, and phosphorylated CREB binds to and activates the cAMP response element (CRE) in rat BDNF promoter III (Shieh et al. 1998; Tao et al. 1998; Shieh and Ghosh 1999; West et al. 2001) . Recently, promoter I was also reported to be CREB-dependent (Tabuchi et al. 2002) . We have identified consensus CRE sites upstream of exons 1 and 3 in the human BDNF gene which suggests the human BDNF gene may be regulated in a manner similar to the rat gene. Levels of phosphorylated CREB are significantly decreased in post-mortem AD brain samples (Yamamoto et al. 1999) , and a recent study demonstrates that Ab(1-42) lowers CREB phosphorylation, causing decreased expression of the exon III BDNF transcript in rat cultured cortical neurons (Tong et al. 2001) . Thus, our data implicating downregulation of transcripts 1 and 3 in reduced BDNF expression in AD are consistent with known BDNF regulation in the rat. On the other hand, the regulatory factors and contribution to CNS BDNF expression for transcript 2 are still unknown.
In summary, we have shown here that only three of the seven human BDNF transcripts expressed in brain are downregulated in AD. Whether the promoters governing these transcripts are regulated in a similar manner in the human CNS and the rat is still unknown. Further investigation will be necessary to identify the factors that regulate the human BDNF gene in AD.
